Pain Medication for CNS/ Neuromusc Dis: 43.3% of denials overturned
In 67 California IMR decisions from 2017 to 2025, reviewers overturned 29 (43.3%). In the last five years: 53.3% of 30. 59 were medical-necessity disputes, 8 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 10 | 80.0% |
| 2022 | 2 | 0.0% |
| 2023 | 9 | 55.6% |
| 2024 | 5 | 0.0% |
| 2025 | 4 | 75.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 23 | 43.5% | 43.3% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 17 | 47.1% | 43.3% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 17 | 58.8% | 43.3% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 13 | 7.7% | 43.3% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 4 | 100.0% | 43.3% |
| Urgent or emergencyThe findings mention urgency. | 3 | 0.0% | 43.3% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 3 | 0.0% | 43.3% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for (1) gabapentin and/or (2) Lyrica. Gabapentin and Lyrica are evidence-based medications used to treat chronic pain, including chronic neuropathic pain from a variety of conditions. Per the medical records, the patient has chronic pain in multiple body parts, along with neuropathic leg pain, that is uncontrolled on …”
“The physician reviewer found that a patient has requested authorization and coverage for hydrocodone acetaminophen 10 mg – 325 mg tablets. Per the medical records, the patient has chronic daily headaches and has tried and failed multiple nonopioid medications including tricyclic antidepressants (TCAs), trazodone, Topamax, gabapentin, Inderal, ketorolac, Fioricet, Flexeril, Lorzone, and Tegretol. The patient has also tried and failed …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for intravenous ketamine infusion. In a systematic review, in 13 of the 14 studies reviewed, ketamine infusion resulted in a decrease in pain scores and relief of symptoms. A systematic review and meta-analysis evaluated randomized clinical trials or cohort studies for meta-analyses. The …”
And one the reviewer upheld
“The physician reviewer found that a patient has requested reimbursement and prospective authorization and coverage for Journavx. Journavx is indicated for the treatment of acute pain. In this case, the patient has chronic, non-malignant musculoskeletal pain. Given that current medical literature does not support Journavx for chronic, long-term use, Journavx is not medically necessary for the treatment of this patient. …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Pain Medication denials for CNS/ Neuromusc Dis overturned?
In 67 California IMR decisions from 2017 to 2025, reviewers overturned 29 (43.3%). In the last five years: 53.3% of 30. 59 were medical-necessity disputes, 8 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.